International Journal of Research in Ayurveda and Pharmacy

ISSN Online:2229-3566

ISSN Print: 2277-4343


Article Category: Original Research articles

DOI: 10.7897/2277-4343.15115

Pages: 69-73

Author: Priyanka Sharma *, Alok Kumar Srivastava, Shashi Kant Tiwari

Abstract: Background: A constellation of conditions known as the Metabolic Syndrome includes hyperglycaemia, elevated blood pressure, insulin resistance, dyslipidaemia and central obesity. The two most significant criteria for this collection are central obesity and insulin resistance. Its frequency quickly increased in the modern period and has had a significant socioeconomic impact. Finding a safe and affordable treatment for Metabolic Syndrome is urgently needed because it is one of the primary risk factors for cardiovascular disease and type 2 diabetes. In the Ayurvedic classics, Santarpana Nimittaj Vikara (diseases due to overeating) is related to Metabolic Syndrome, and Lekhana Basti (therapeutic enema with scrapping properties) appears to be an effective treatment because it is one of the fastest methods to achieve apatarpana (fasting). Objective: The objective of the study is to evaluate the role of Lekhana Basti in Metabolic Syndrome. Material and methods: Patients of either sex who fulfilled the study's eligibility requirements and were aged between 20-60 years were enrolled. Lekhana Basti was given to each of the 21 patients in the morning for 15 days, along with Matra Basti (a type of oleaginous enema) in the evening. The same method was then done after a 15-day break. The final result was then seen after 15 days. Results: In terms of the criteria for weight, waist size, blood sugar fasting, and diastolic blood pressure, the intervention is highly significant; in terms of systolic blood pressure and LDL, it is significant; and in terms of triglycerides and HDL, it is not significant. Conclusion: Lekhana Basti is an ideal therapy for Metabolic Syndrome.

Keyword: Metabolic Syndrome, Insulin resistance, Lekhana Basti, Santarpana Nimittaj Vikara, Type 2 Diabetes Mellitus